{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Préménopause : Questions médicales les plus fréquentes",
"headline": "Préménopause : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Préménopause : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-01-13",
"dateModified": "2026-07-01",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Préménopause"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Ménopause",
"url": "https://questionsmedicales.fr/mesh/D008593",
"about": {
"@type": "MedicalCondition",
"name": "Ménopause",
"code": {
"@type": "MedicalCode",
"code": "D008593",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "G08.686.841.249.500"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Préménopause",
"alternateName": "Premenopause",
"code": {
"@type": "MedicalCode",
"code": "D017697",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Adetunji T Toriola",
"url": "https://questionsmedicales.fr/author/Adetunji%20T%20Toriola",
"affiliation": {
"@type": "Organization",
"name": "Division of Public Health Sciences, Department of Surgery, School of Medicine, Washington University, 660 South Euclid Avenue, Box 8100, St. Louis, MO, 63110, USA. a.toriola@wustl.edu."
}
},
{
"@type": "Person",
"name": "Carin Y Smith",
"url": "https://questionsmedicales.fr/author/Carin%20Y%20Smith",
"affiliation": {
"@type": "Organization",
"name": "Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota."
}
},
{
"@type": "Person",
"name": "Liliana Gazzuola Rocca",
"url": "https://questionsmedicales.fr/author/Liliana%20Gazzuola%20Rocca",
"affiliation": {
"@type": "Organization",
"name": "Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota."
}
},
{
"@type": "Person",
"name": "Walter A Rocca",
"url": "https://questionsmedicales.fr/author/Walter%20A%20Rocca",
"affiliation": {
"@type": "Organization",
"name": "Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota."
}
},
{
"@type": "Person",
"name": "Michelle M Mielke",
"url": "https://questionsmedicales.fr/author/Michelle%20M%20Mielke",
"affiliation": {
"@type": "Organization",
"name": "Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Patient-reported outcome and survival in premenopausal hormone receptor-positive breast cancer patients at moderate to high risk: comparing toremifene with aromatase inhibitor in a real-world study.",
"datePublished": "2024-09-15",
"url": "https://questionsmedicales.fr/article/39286777",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/mco2.698"
}
},
{
"@type": "ScholarlyArticle",
"name": "Endocrine profile of the kisspeptin receptor agonist MVT-602 in healthy premenopausal women with and without ovarian stimulation: results from 2 randomized, placebo-controlled clinical tricals.",
"datePublished": "2023-11-03",
"url": "https://questionsmedicales.fr/article/37925096",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.fertnstert.2023.10.031"
}
},
{
"@type": "ScholarlyArticle",
"name": "What happens after menopause? (WHAM): A prospective controlled study of vasomotor symptoms and menopause-related quality of life 24 months after premenopausal risk-reducing salpingo-oophorectomy (RRSO).",
"datePublished": "2024-10-22",
"url": "https://questionsmedicales.fr/article/39442373",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.ygyno.2024.10.007"
}
},
{
"@type": "ScholarlyArticle",
"name": "Comprehensive Analysis of Iron Deficiency Anemia and Its Related Disorders in Premenopausal Women Based on a Propensity Score Matching Case Control Study Using National Health Insurance Service Database in Korea.",
"datePublished": "2023-09-18",
"url": "https://questionsmedicales.fr/article/37724497",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3346/jkms.2023.38.e299"
}
},
{
"@type": "ScholarlyArticle",
"name": "Palbociclib combined with endocrine treatment in hormone receptor-positive, HER2-negative breast cancer patients with high relapse risk after neoadjuvant chemotherapy: subgroup analyses of premenopausal patients in PENELOPE-B.",
"datePublished": "2024-06-04",
"url": "https://questionsmedicales.fr/article/38838498",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.esmoop.2024.103466"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Phénomènes physiologiques des appareils urinaire et reproducteur",
"item": "https://questionsmedicales.fr/mesh/D012101"
},
{
"@type": "ListItem",
"position": 3,
"name": "Phénomènes physiologiques de la reproduction",
"item": "https://questionsmedicales.fr/mesh/D055703"
},
{
"@type": "ListItem",
"position": 4,
"name": "Développement sexuel",
"item": "https://questionsmedicales.fr/mesh/D046468"
},
{
"@type": "ListItem",
"position": 5,
"name": "Climatère",
"item": "https://questionsmedicales.fr/mesh/D002979"
},
{
"@type": "ListItem",
"position": 6,
"name": "Ménopause",
"item": "https://questionsmedicales.fr/mesh/D008593"
},
{
"@type": "ListItem",
"position": 7,
"name": "Préménopause",
"item": "https://questionsmedicales.fr/mesh/D017697"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Préménopause - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Préménopause",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2026-08-25",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Préménopause",
"description": "Comment diagnostiquer la préménopause ?\nQuels tests sont utilisés pour la préménopause ?\nLes symptômes peuvent-ils varier d'une femme à l'autre ?\nQuand consulter un médecin pour des symptômes ?\nLa préménopause peut-elle être confondue avec d'autres conditions ?",
"url": "https://questionsmedicales.fr/mesh/D017697?page=17#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Préménopause",
"description": "Quels sont les symptômes courants de la préménopause ?\nLes troubles du sommeil sont-ils fréquents ?\nLa prise de poids est-elle un symptôme ?\nLes changements d'humeur sont-ils normaux ?\nLes douleurs mammaires sont-elles un symptôme ?",
"url": "https://questionsmedicales.fr/mesh/D017697?page=17#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Préménopause",
"description": "Peut-on prévenir les symptômes de la préménopause ?\nL'exercice régulier aide-t-il à prévenir les symptômes ?\nUne alimentation saine peut-elle faire une différence ?\nLe stress influence-t-il les symptômes ?\nLes suppléments peuvent-ils aider à prévenir les symptômes ?",
"url": "https://questionsmedicales.fr/mesh/D017697?page=17#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Préménopause",
"description": "Quels traitements sont disponibles pour la préménopause ?\nLa thérapie hormonale est-elle sûre ?\nLes remèdes naturels sont-ils efficaces ?\nComment les changements de mode de vie aident-ils ?\nLes antidépresseurs peuvent-ils aider ?",
"url": "https://questionsmedicales.fr/mesh/D017697?page=17#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Préménopause",
"description": "Quelles complications peuvent survenir pendant la préménopause ?\nLa préménopause augmente-t-elle le risque de dépression ?\nLes problèmes de fertilité peuvent-ils survenir ?\nLes maladies cardiovasculaires sont-elles un risque ?\nComment prévenir l'ostéoporose durant cette période ?",
"url": "https://questionsmedicales.fr/mesh/D017697?page=17#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Préménopause",
"description": "Quels sont les facteurs de risque de la préménopause ?\nLe tabagisme influence-t-il la préménopause ?\nL'obésité est-elle un facteur de risque ?\nLe stress chronique affecte-t-il la préménopause ?\nLes antécédents médicaux influencent-ils la préménopause ?",
"url": "https://questionsmedicales.fr/mesh/D017697?page=17#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer la préménopause ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur l'évaluation des symptômes et des tests hormonaux."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour la préménopause ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests sanguins mesurant les niveaux d'œstrogènes et de FSH sont courants."
}
},
{
"@type": "Question",
"name": "Les symptômes peuvent-ils varier d'une femme à l'autre ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes de la préménopause peuvent différer considérablement entre les femmes."
}
},
{
"@type": "Question",
"name": "Quand consulter un médecin pour des symptômes ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Consultez un médecin si les symptômes perturbent votre qualité de vie."
}
},
{
"@type": "Question",
"name": "La préménopause peut-elle être confondue avec d'autres conditions ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut être confondue avec des troubles thyroïdiens ou des troubles de l'humeur."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes courants de la préménopause ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent des bouffées de chaleur, des irrégularités menstruelles et des sautes d'humeur."
}
},
{
"@type": "Question",
"name": "Les troubles du sommeil sont-ils fréquents ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, de nombreuses femmes éprouvent des troubles du sommeil durant la préménopause."
}
},
{
"@type": "Question",
"name": "La prise de poids est-elle un symptôme ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des changements hormonaux peuvent entraîner une prise de poids pendant cette période."
}
},
{
"@type": "Question",
"name": "Les changements d'humeur sont-ils normaux ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les fluctuations hormonales peuvent provoquer des changements d'humeur fréquents."
}
},
{
"@type": "Question",
"name": "Les douleurs mammaires sont-elles un symptôme ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines femmes ressentent des douleurs mammaires dues aux fluctuations hormonales."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les symptômes de la préménopause ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Bien qu'on ne puisse pas prévenir la préménopause, un mode de vie sain peut aider."
}
},
{
"@type": "Question",
"name": "L'exercice régulier aide-t-il à prévenir les symptômes ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exercice régulier peut réduire l'intensité des symptômes de la préménopause."
}
},
{
"@type": "Question",
"name": "Une alimentation saine peut-elle faire une différence ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une alimentation riche en nutriments peut atténuer certains symptômes."
}
},
{
"@type": "Question",
"name": "Le stress influence-t-il les symptômes ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress peut aggraver les symptômes de la préménopause. La gestion du stress est cruciale."
}
},
{
"@type": "Question",
"name": "Les suppléments peuvent-ils aider à prévenir les symptômes ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certains suppléments, comme les oméga-3, peuvent aider à atténuer les symptômes."
}
},
{
"@type": "Question",
"name": "Quels traitements sont disponibles pour la préménopause ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent des thérapies hormonales, des médicaments et des changements de mode de vie."
}
},
{
"@type": "Question",
"name": "La thérapie hormonale est-elle sûre ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "La thérapie hormonale peut être efficace, mais elle comporte des risques. Consultez un médecin."
}
},
{
"@type": "Question",
"name": "Les remèdes naturels sont-ils efficaces ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certains remèdes naturels peuvent soulager les symptômes, mais leur efficacité varie."
}
},
{
"@type": "Question",
"name": "Comment les changements de mode de vie aident-ils ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée et l'exercice régulier peuvent atténuer les symptômes."
}
},
{
"@type": "Question",
"name": "Les antidépresseurs peuvent-ils aider ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains antidépresseurs peuvent soulager les symptômes d'humeur liés à la préménopause."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir pendant la préménopause ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications comme l'ostéoporose et les maladies cardiaques peuvent survenir."
}
},
{
"@type": "Question",
"name": "La préménopause augmente-t-elle le risque de dépression ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les fluctuations hormonales peuvent augmenter le risque de dépression chez certaines femmes."
}
},
{
"@type": "Question",
"name": "Les problèmes de fertilité peuvent-ils survenir ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la fertilité peut diminuer pendant la préménopause en raison de changements hormonaux."
}
},
{
"@type": "Question",
"name": "Les maladies cardiovasculaires sont-elles un risque ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le risque de maladies cardiovasculaires peut augmenter pendant la préménopause."
}
},
{
"@type": "Question",
"name": "Comment prévenir l'ostéoporose durant cette période ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un apport adéquat en calcium et en vitamine D, ainsi que l'exercice, peuvent aider."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque de la préménopause ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent l'âge, les antécédents familiaux et le mode de vie."
}
},
{
"@type": "Question",
"name": "Le tabagisme influence-t-il la préménopause ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le tabagisme peut précipiter l'apparition des symptômes de la préménopause."
}
},
{
"@type": "Question",
"name": "L'obésité est-elle un facteur de risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'obésité peut augmenter le risque de symptômes sévères durant la préménopause."
}
},
{
"@type": "Question",
"name": "Le stress chronique affecte-t-il la préménopause ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress chronique peut aggraver les symptômes et affecter la santé globale."
}
},
{
"@type": "Question",
"name": "Les antécédents médicaux influencent-ils la préménopause ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents médicaux comme des troubles hormonaux peuvent influencer la préménopause."
}
}
]
}
]
}
Toremifene, a selective estrogen receptor modulator, is commonly used in China for premenopausal breast cancer patients. This real-world study aimed to compare patient-reported outcome (PRO) and survi...
Kisspeptin is an essential regulator of hypothalamic gonadotropin-releasing hormone release and is required for physiological ovulation. Native kisspeptin-54 can induce oocyte maturation during in vit...
To determine the endocrine profile of MVT-602 in the follicular phase of healthy premenopausal women (phase-1 trial), and after minimal ovarian stimulation to more closely reflect the endocrine milieu...
Two randomized, placebo-controlled, parallel-group, dose-finding trials....
Clinical trials unit....
Healthy women aged 18-35 years, either without (phase-1; n = 24), or with ovarian stimulation (phase-2a; n = 75)....
Phase-1: single subcutaneous dose of MVT-602 (0.3, 1.0, or 3.0 μg) or placebo, (n = 6 per dose). Phase-2a: single subcutaneous dose of MVT-602 (0.1, 0.3, 1.0, or 3.0 μg; n = 16-17 per dose), triptorel...
Phase-1: safety/tolerability; pharmacokinetics; and pharmacodynamics (luteinizing hormone [LH] and other reproductive hormones). Phase-2a: safety/tolerability; pharmacokinetics; pharmacodynamics (LH a...
In both the trials, MVT-602 was safe and well tolerated across the entire dose range. It was rapidly absorbed and eliminated, with a mean elimination half-life of 1.3-2.2 hours. In the phase-2a trial,...
MVT-602 induces LH concentrations of similar amplitude and duration as the physiological midcycle LH surge with potential utility for induction of oocyte maturation and ovulation during MAR....
EUDRA-CT: 2017-003812-38, 2018-001379-20....
To measure vasomotor symptoms and menopause-related quality of life up to 24 months after RRSO, and the effects of Menopausal Hormone Therapy (MHT)....
Prospective observational study of 104 premenopausal women at elevated risk of ovarian cancer planning RRSO and age-matched comparators (n = 102) who retained their ovaries. Vasomotor symptoms and qua...
At 24 months after RRSO the prevalence of vasomotor symptoms had increased from 6 % at baseline to 59 % and night sweats from 21 % to 39 %. There was a clinically and statistically significant differe...
Vasomotor symptoms peak by 3 months after RRSO and are stable over 24 months. MHT mitigates but does not fully resolve vasomotor symptoms and improves menopause-related QoL....
Menorrhagia is a common cause of iron deficiency anemia (IDA) in premenopausal women. However, the effects of menorrhagia on IDA in premenopausal women have been underestimated compared to those on ot...
From 2005 to 2008, data about women between the age of 20 and 59 years were extracted from the NHIS-NHID to create a propensity score-matched case (IDA) and control group. The annual incidence of IDA ...
From 2005 to 2008, women diagnosed with IDA (n = 535,249) and healthy women as a control group (n = 1,070,498) were identified from the NHIS-NHID. The annual incidence of IDA was 767.4 (2005), 948.7 (...
In this study, we found that the gynecologic disease is the main cause of IDA in premenopausal women. Gynecological evaluations should be performed more actively in the clinic to prevent and control I...
The PENELOPE-B study demonstrated that the addition of 1-year post-neoadjuvant palbociclib to endocrine therapy (ET) in patients with high-risk early breast cancer (BC) did not improve invasive diseas...
Patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative BC at high risk of relapse [defined as no pathological complete response after neoadjuvant chemotherapy and a...
Overall, 616 of 1250 randomized patients were premenopausal; of these, 30.0% were <40 years of age, 47.4% had four or more metastatic lymph nodes, and 58.2% had a CPS-EG score ≥3. 66.1% of patients we...
In premenopausal women, who received tamoxifen plus OFS as ET, the addition of palbociclib to ET results in a favorable iDFS. The safety profile seems favorable and in contrast to chemotherapy palboci...
The only phase 3 study on the effectiveness of CDK 4-6 inhibitors in first-line treatment in premenopausal patients with hormone receptor (HR) positive, HER2 negative metastatic breast cancer is the M...
Hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-positive (HER2+) breast cancer exhibits considerable heterogeneity, and it is of great interest whether patients with premenopa...
Multicenter data from 253 premenopausal patients with HR+/HER2+ early-stage breast cancer who received trastuzumab from October 2009 to October 2018 were retrospectively included. The Kaplan-Meier met...
After a median follow-up of 98.50 months, compared with tamoxifen/toremifene alone, tamoxifen/toremifene/aromatase inhibitors plus OFS demonstrated significant benefits in the overall study population...
For premenopausal HR+ breast cancer patients, HER2 positivity alone is an indication for the addition of OFS in adjuvant endocrine therapy. Age, histological grade, lymph node status, the expression o...